Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2026)

Enanta Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $52.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 6.65% year-over-year to $52.8 million; the trailing twelve-month figure through Mar 2026 stood at $52.8 million (down 6.65% YoY), and the FY2025 full-year result was $54.8 million, up 1.51% from the prior year.
• Operating Leases for Q1 2026 stood at $52.8 million, down from $53.8 million in the prior quarter.
• The five-year high for Operating Leases was $56.5 million in Q1 2025, with the low at $15.1 million in Q1 2022.
• Historically, Operating Leases has averaged $37.9 million across 5 years, with a median of $43.4 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases surged 1886.86% — and 2026, when it dropped 6.65%.
• Enanta Pharmaceuticals' Operating Leases stood at $21.9 million in 2022, then retreated by 6.11% to $20.5 million in 2023, then soared by 175.06% to $56.5 million in 2024, then retreated by 4.73% to $53.8 million in 2025, then dropped by 1.87% to $52.8 million in 2026.
• The last three Operating Leases figures came in at $52.8 million (Q1 2026), $53.8 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.